SM-164 is a potent cell-permeable and bivalent Smac mimetic which bind to a XIAP protein with a Ki value of 0.56nM, and binds to cIAP-1 and cIAP-2 proteins with Ki values of 0.31 and 1.1nM, respectively
信号通路
Apoptosis
靶点
XIAP
cIAP-1
cIAP-2
-
-
IC50
0.56nM(Ki)
0.31nM(Ki)
1.1nM(Ki)
-
-
体外研究
SM-164 induced complete cIAP-1 degradation, it displayed weak inhibitory effects on the viability of HCC cells. Nevertheless, SM-164 considerably potentiated Apo2 ligand or TNF-related apoptosis-inducing ligand (APO2L/TRAIL)- and Doxorubicin-mediated anticancer activity in HCC cells. Mechanistic studies demonstrated that SM-164 in combination with chemotherapeutic agents resulted in enhanced activation of caspases-9, -3 and cleavage of poly ADP-ribose polymerase (PARP), and also led to decreased AKT activation. Although SM-164 is modestly more effective than SM-122 in induction of cIAP-1/2 degradation, SM-164 is 1,000 times more potent than SM-122 as an inducer of apoptosis in tumor cells, which is attributed to its much higher potency in binding to and antagonizing XIAP. SM-164 radiosensitization in sensitive cells was associated with NF-κB activation and TNFα secretion, followed by activation of caspase-8 and -9, leading to enhanced apoptosis.
体内研究
SM-164 induces rapid cIAP-1 degradation and strong apoptosis in the MDA-MB-231 xenograft tumor tissues and achieves tumor regression, but has no toxicity in normal mouse tissues. SM-164 also radiosensitized human tumor xenograft while causing minimal toxicity.
临床实验
N/A
特征
N/A
相关实验数据(此数据来自于公开文献，碧云天并不保证其有效性)：
▼
▲
酶活性检测实验
方法
N/A
▼
▲
细胞实验
细胞系
N/A
浓度
N/A
处理时间
N/A
方法
N/A
▼
▲
动物实验
动物模型
N/A
配制
N/A
剂量
N/A
给药方式
N/A
参考文献： 1. Lu J, et al. SM-164: a novel, bivalent Smac mimetic that induces apoptosis and tumor regression by concurrent removal of the blockade of cIAP-1/2 and XIAP. Cancer Res. 2008 Nov 15; 68(22):9384-93. 2. Yang J, et al. Radiosensitization of head and neck squamous cell carcinoma by a SMACmimetic compound, SM-164, requires activation of caspases. Mol Cancer Ther. 2011 Apr; 10(4):658-69. 3. Zhang S, et al. Smac mimetic SM-164 potentiates APO2L/TRAIL-and doxorubicin-mediated anticancer activity in human hepatocellular carcinoma cells. PLoS One. 2012; 7(12):e51461. 包装清单：
